• Iovance Biotherapeutics (NASDAQ:IOVA) is down 12% in after-hours trading Thursday despite posting Q3 results that beat on both lines and reaffirming its fiscal 2024 revenue guidance.
• The biotech still sees full-year product sales of $160M-$165M. Revenue consensus is $162.71M. The company also reiterated its

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。